CAS NO: | 1061353-68-1 |
规格: | ≥98% |
包装 | 价格(元) |
1mg | 电议 |
2mg | 电议 |
5mg | 电议 |
10mg | 电议 |
25mg | 电议 |
50mg | 电议 |
100mg | 电议 |
250mg | 电议 |
500mg | 电议 |
Molecular Weight (MW) | 501.5 |
---|---|
Formula | C25H26F3N5O3 |
CAS No. | 1061353-68-1 |
Storage | -20℃ for 3 years in powder form |
-80℃ for 2 years in solvent | |
Solubility (In vitro) | DMSO: 24 mg/mL (47.8 mM) |
Water: <1 mg/mL | |
Ethanol: <1 mg/mL | |
Solubility (In vivo) | 2% DMSO+30% PEG 300+5% Tween 80+ddH2O: 5mg/mL |
Synonyms | SR-2156; VS-4718; PND-1186; PND 1186; PND1186; SR 2516; SR2516; VS4718; VS 4718. Chemical Name: 2-((2-((2-methoxy-4-morpholinophenyl)amino)-5-(trifluoromethyl)pyridin-4-yl)amino)-N-methylbenzamide. InChi Key: IGUBBWJDMLCRIK-UHFFFAOYSA-N InChi Code: InChI=1S/C25H26F3N5O3/c1-29-24(34)17-5-3-4-6-19(17)31-21-14-23(30-15-18(21)25(26,27)28)32-20-8-7-16(13-22(20)35-2)33-9-11-36-12-10-33/h3-8,13-15H,9-12H2,1-2H3,(H,29,34)(H2,30,31,32) SMILES Code: O=C(NC)C1=CC=CC=C1NC2=CC(NC3=C(OC)C=C(N4CCOCC4)C=C3)=NC=C2C(F)(F)F |
In Vitro | In vitro activity: In vitro, PND-1186 inhibits 4T1 breast carcinoma motility, promotes 4T1 apoptosis in suspended conditions, and decreases 4T1 soft agar colony number and size. In HEY and OVCAR8 cells, VS-4718 promotes G0-G1 cell-cycle arrest followed by cell death. Kinase Assay: GST-FAK in vitro kinase activity is measured and compared to His-tagged FAK 411–686 using the K-LISA screening kit and poly(Glu:Tyr) (4:1) copolymer as a substrate immobilized on microtiter plates. IC50 values are determined with various concentrations of test compounds in a buffer containing 50 μM ATP and 10 mM MnCl2, 50 mM HEPES (pH 7.5), 25 mM NaCl, 0.01% BSA, and 0.1 mM Na orthovanadate for 5 min at room temperature. Serial diluted compounds are tested in triplicate. Substrate phosphorylation is measured using horseradish peroxidase-conjugated anti-pTyr antibodies with spetrophotometric color quantitation. IC50 values are determined using the Hill-Slope Model. Kinase selectivity profiling is performed by using the KinaseProfiler service. Cell Assay: For soft agar assays, 48-well plates are coated with a 1:4 mix of 2% agar (EM Science) in 0.2 mL growth media (bottom layer). 5×104 cells are plated per well (in triplicate) in a mixture of 0.3% agar in 0.2 mL growth media (top layer). After agar solidification, 0.2 mL growth media is added containing DMSO or PND-1186 (final concentration for 0.6 mL). In separate experiments, PND-1186 is added after 4 days. After 10 days, colonies are imaged in phase contrast, enumerated by counting 9 fields (3 fields per well), and total area determined using Image J. For all analyses, experimental points are performed in triplicate and repeated at least two times. |
---|---|
In Vivo | In mice bearing 4T1 tumors, PND-1186 (100 mg/kg s.c.) inhibits 4T1 subcutaneous tumor growth by induction of apoptosis. In mice bearing ID8 tumors, PND-1186 (0.5 mg/mL for p.o.) also causes ovarian carcinoma tumor growth inhibition. |
Animal model | Mice bearing ID8 tumors or 4T1 tumors |
Formulation & Dosage | Dissolved in polyethylene glycol 400 (PEG400) in PBS (1:1) for s.c.; 5% sucrose for p.o.; 100 mg/kg every 12 hours for s.c.; 0.5 mg/mL for p.o.; Administered via s.c. or p.o. |
References | Cancer Biol Ther. 2010 May 15;9(10):764-77; Mol Cancer Ther. 2014 Aug;13(8):2050-61. |
PND-1186 inhibitory effects differ from Dasatinib (Src inhibition). Cancer Biol Ther. 2010 May; 9(10): 764–777. | PND-1186 inhibits ovarian carcinoma tumor growth. Cancer Biol Ther. 2010 May; 9(10): 764–777. Cancer Biol Ther. 2010 May 15;9(10):764-77. | Selective 4T1 cell apoptosis in suspension at low PND-1186 levels. Cancer Biol Ther. 2010 May 15;9(10):764-77. |